An interventional study of Magnetic stimulation and Sham Magnetic stimulation in Stress Urinary Incontinence, Urgency Urinary Incontinence and Mixed Urinary Incontinence, sponsored by Sunnybrook Health Sciences Centre. Enrolling by invitation at 1 site in Canada. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-27.
Sponsored by Sunnybrook Health Sciences Centre · Not applicable, Interventional, and Treatment
Among 47 studies in Urinary Incontinence, Stress with a site in Canada — 6 open to participants now, 10 under way, 1 of them phase 3. Urinary Incontinence, Stress · Canada.
Among the 47 studies in Urinary Incontinence, Stress with a site in Canada, this one is the 10th largest by planned enrollment of the 40 interventional ones that give a count, is the only one that started in 2023, is one of 28 with no phase, and was the 41st registered.
653 studies on the registry are indexed under Urinary Incontinence, Stress; 121 are open to participants now.
Browse Urinary Incontinence, Stress studies →6 of the 47 studies in Urinary Incontinence, Stress with a site in Canada are open now. Recruiting first, the newest first:
University of Ottawa · Sites in Canada
Ages 18+ · Women only · Healthy volunteers
Eli Lilly and Company · Sites in Canada, United States, China and 6 more countries
Ages 18+ · Women only
University of Ottawa · Sites in Canada
Ages 18–40 · Women only · Healthy volunteers
University of Ottawa · Sites in Canada
Ages 18+ · Women only
Sunnybrook Health Sciences Centre · Sites in Canada
Ages 18+ · Women only
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 74 Urinary Incontinence, Stress studies recruiting now, 42 (57%) set no upper age limit and 18 (24%) stop at 75 or younger; 2 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 220 is above the median of 68 across 508 interventional studies indexed under Urinary Incontinence, Stress.
Median enrollment 86 across the 40 interventional studies, 108 across the 6 observational. Of the 32 that completed or were terminated, 13 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 47 have an industry lead sponsor. The 10 most frequent:
Sunnybrook Health Sciences Centre is the lead sponsor of 584 studies on the registry; 135 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
Sunnybrook Health Sciences Centre has 4 studies filed under Urinary Incontinence, Stress — fewer than ten, so there is no comparison to draw.
3 of the studies in Urinary Incontinence, Stress with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07727460University of OttawaThe Reliability of Pelvic Floor Measures From Ultrasound Images Acquired at Rest and During Weightlifting Tasks. | 2026-11-30 |
| NCT07427693Centre de Recherche de l'Institut Universitaire de Geriatrie de MontrealUsability, Acceptability and Effect of a Mobile Application and Connected Object for Older Women With UI | 2026-12-31 |
| NCT05952258Sunnybrook Health Sciences CentreMagnetic Stimulation as a Treatment for Female Urinary Incontinence | 2027-07-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 47 studies in Urinary Incontinence, Stress with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to determine the efficacy of electromagnetic stimulation treatment of the pelvic floor muscles in adult females with urinary incontinence.
A double-blinded randomized controlled clinical trial with a treatment arm and a sham treatment arm will be conducted; followed by an open label trial at 3 months for any sham treatment arm participants who do not meet treatment success.
The primary goal is to compare the subjective success rates for the resolution of female urinary incontinence (UI) for the magnetic stimulation treatment at 3 months. Secondary aims include an assessment of complications, resolution of UI symptoms, patient bother from UI, quality of life and patient satisfaction. The proposed sample size is 220 patients. At the 3-month post treatment evaluation, the treatment allocation will be unmasked. Patients will be followed post treatment up to 2 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1) Non-pregnant adult female, not planning pregnancy during the duration of the study 2) primary symptoms of SUI, UUI, MUI (with SUI predominant symptoms) or MUI (with UUI predominant symptoms), as confirmed by history, focused evaluation for ≥3 months 3) objective proof of SUI: Observation of urine leakage by cough and valsalva (positive stress test) at a bladder volume of ≤ 300cc 4) Bladder capacity ≥200cc 5) Post void residual ≤100cc with Stage I or lower pelvic organ prolapse 6) For those with UUI symptoms: Post void residual ≤100cc with Stage I or lower pelvic organ prolapse 7) No concurrent or new planned treatment for UI during the treatment period and the 3 months following it 7) No known body metal from umbilicus to knees 8) Willing and able to comply with the protocol
Exclusion Criteria:
1) Patient is pregnant, lactating, or plans to become pregnant during the Study; or Patient is \<12 months post partum 2) Patient has other predominant type of UI (e.g. overflow UI, fistula) 3) Current chemo/radiotherapy; history of pelvic radiation; or pelvic surgery \< 3 months 4) Systemic diseases known to affect bladder function (e.g. Parkinson's disease, multiple sclerosis, spina bifida, spinal cord injury) 5) Current or history of urethral diverticulum, prior augmentation cystoplasty, implanted nerve stimulators for bladder symptoms 6) Current evaluation or treatment for chronic pelvic pain 7) Participation in another treatment intervention that might interfere with the results of this trial 8) Patient has a medical condition or disorder that may cause non-compliance with the protocol (e.g. unable to perform self-evaluations and/or accurately report medical history, and/or data). 9) Patient has ambulatory 24-hour pad test, where the increased pad weight is \< 3 grams. 10) Patient is non-ambulatory (ambulatory with assistive devices allowed) or unable to sit in a chair independently 12) Known body metal located from umbilicus to knees, or cardiac pacemaker 13) Previous magnetic stimulation therapy
Participants will sit fully clothed on the magnetic stimulator chair, with knees apart at about the width of their shoulders, feet flat on the floor. The stimulator will be activated and the intensity gradually increased as tolerated by the participant up to an intensity of 100%. There are a total of 6 treatment sessions (twice per week) over 3 weeks.
Device: Magnetic stimulation
Participants will sit fully clothed on the magnetic stimulator chair, with knees apart at about the width of their shoulders, feet flat on the floor. The stimulator will be activated and the intensity gradually increased as tolerated by the participant up to an intensity of 5%. There are a total of 6 treatment sessions (twice per week) over 3 weeks.
Device: Sham Magnetic stimulation
The magnetic stimulation to the pelvic floor muscle will be provided by the Emsella® chair: which will be activated for 28 minutes at each treatment session. The treatment arm will receive up to 100% intensity at each treatment session.
The sham arm will receive up to 5% intensity at each treatment session
ICIQ-SF (standardized, validated questionnaire)
The reporting by the patients of a "cure" of stress urinary incontinence at T3 (question #3 of the International Consultation on Incontinence Questionnaire, ICIQ-SF). For those with Urgency urinary incontinence (UUI) we have chosen subjective improvement in symptoms of UI as indicated by the change in ICIQ-SF total score.
Time frame: 3 months post treatment
UDI-6
(standardized, validated questionnaire)
Time frame: 3, 6, 12 and 24 months post treatment
IIQ-7
(standardized, validated questionnaire)
Time frame: 3, 6, 12 and 24 months post treatment
ICIQ-LUTS-qol
(standardized, validated questionnaire)
Time frame: 3, 6, 12 and 24 months post treatment
PGI-I
(standardized, validated questionnaire)
Time frame: 3, 6, 12 and 24 months post treatment
PISQ-12
(standardized, validated questionnaire)
Time frame: 3, 6, 12 and 24 months post treatment
24 hour pad test
an objective measure of incontinence and its severity
Time frame: 3 and 12 months
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2023 (actual). Primary completion is estimated for Jul 2027, 46 months after the start.
Of 226 non-industry interventional studies with no phase under Urinary Incontinence, Stress, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 46 months is above that.
Counting every sponsor, half of 267 studies reached it within 19 months; a quarter within 9 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Urinary Incontinence, Stress →
Sunnybrook Health Sciences Centre →